Cardiac function of long-responders to dual anti-HER2 antibodies amongst patients with HER2 positive advanced breast cancer

被引：0
|
作者：
Bao, Kelvin K. H. [1 ]
Chan, Jeffrey C. H. [1 ]
Sutanto, Leone [1 ]
Chan, Jocelyn G. [1 ]
Cheung, Ka Man [1 ]
Yiu, Harry H. Y. [1 ]
机构：
[1] Queen Elizabeth Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1043
引用
收藏
页数：1
相关论文
共 50 条
  • [21] ESAM reduces anti-HER2 therapy sensitivity by activating mTOR pathway in HER2 positive breast cancer
    Wu, Jiong
    Zhou, Xujie
    Chi, Yayun
    Xue, Jingyan
    CANCER RESEARCH, 2023, 83 (05)
  • [22] Treatment of HER2 positive stage 4 breast cancer: When to stop anti-HER2 agents.
    Kamada, Yoshihiko
    Takigami, Naoko
    Uehara, Kanou
    Tamaki, Kentaro
    Tamaki, Nobumitsu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] HER2 testing and its predictive utility in anti-HER2 breast cancer therapy
    Advani, Pooja P.
    Crozier, Jennifer A.
    Perez, Edith A.
    BIOMARKERS IN MEDICINE, 2015, 9 (01) : 35 - 49
  • [24] Sparing chemotherapy with dual HER2 blockade in combination with endocrine therapy for advanced HER2 positive breast cancer
    Werutsky, Gustavo
    Reinert, Tomas
    Fay, Andre Poisl
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S573 - S576
  • [25] HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
    Novillo, Apolonia
    Gaibar, Maria
    Romero-Lorca, Alicia
    Malon, Diego
    Anton, Beatriz
    Moreno, Amalia
    Fernandez-Santander, Ana
    CANCERS, 2023, 15 (03)
  • [26] Safety and effectiveness of anti-HER2 therapy in patients with advanced metastatic tissue HER2-negative breast cancer with elevated serum HER2 and/or HER2 overexpressing circulating tumor cells
    Kurbacher, C. M.
    Eichler, C.
    Quade, A. B.
    Kunstmann, G.
    Herz, S.
    Kurbacher, J. A.
    Warm, M. R.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S40 - S40
  • [27] Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts
    Barbieri, E.
    Piacentini, F.
    Dieci, M. V.
    Ficarra, G.
    Bettelli, S.
    Conte, P.
    Guarneri, V.
    CANCER RESEARCH, 2011, 71
  • [28] Cardiac function in patients receiving dual anti-Her2 antibodies (trastuzumab and pertuzumab) combined with chemotherapy for breast cancer in routine practice.
    Zekri, Jamal
    Rasool, Haleem J.
    Rizvi, Syed Azhar J.
    Mahmoud, Ehab Mosaad Abdel Ghany
    Rasmy, Ayman Ahamd
    Al-Gahmi, Aboelkhair
    Farag, Kamel
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer
    Musolino, Antonino
    Boggiani, Daniela
    Pellegrino, Benedetta
    Zanoni, Daniele
    Sikokis, Angelica
    Missale, Gabriele
    Silini, Enrico Maria
    Maglietta, Giuseppe
    Frassoldati, Antonio
    Michiara, Maria
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 149
  • [30] Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution
    Giugliano, Federica
    Carnevale Schianca, Ambra
    Corti, Chiara
    Ivanova, Mariia
    Bianco, Nadia
    Dellapasqua, Silvia
    Criscitiello, Carmen
    Fusco, Nicola
    Curigliano, Giuseppe
    Munzone, Elisabetta
    CANCERS, 2023, 15 (05)
12345